Is Johnson & Johnson a Buy After Its Latest Earnings Report?
Investors didn't seem to think so after the company published it.
Read the full articleYou might also wanna read
J&J Stock Slips Despite Earnings Beat as Company Raises Guidance Toward $100 Billion Sales Milestone Today
Johnson & Johnson's stock fell despite exceeding Q2 earnings expectations, as investor optimism had already been priced in. The company rais
Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc li
Why Johnson & Johnson (JNJ) Stock Declined Despite Strong Q2 Earnings Beat
Johnson & Johnson (JNJ) shares fell 2% despite beating Q2 estimates with $2.90 EPS and $25.31B revenue, while raising full-year guidance on
Johnson & Johnson (JNJ) Stock Down 0.8% but Still Overvalued -- GF Score: 81/100
Related Stocks: JNJ
The Real Case for Buying Johnson & Johnson (JNJ) Before July 15
Johnson & Johnson (NYSE:JNJ) is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the setu
J&J quarterly earnings beat Wall Street estimates on strength of medicines unit
By Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as stron
Comments
Sign in to join the conversation.
No comments yet. Be the first.